In summary, our study showed that although CLL cells with loss of p53 were resistant to conventional anti-CLL drugs such as F-ara-A, Oxaliplatin and Bendamustine, these leukemia cells remain sensitive to PEITC, even when CLL cell was under the protection of bone marrow stromal cells. This evidence concerns the gene TP53 and leukemia.